Acurx Pharmaceuticals Inc...

NASDAQ: ACXP · Real-Time Price · USD
5.11
0.25 (5.14%)
At close: Aug 15, 2025, 3:59 PM
5.12
0.20%
After-hours: Aug 15, 2025, 05:58 PM EDT

Acurx Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Gross Profit
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Income
-10.02M -11.88M -14.1M -16.44M -16.73M -16.05M -14.58M -12.72M -13.15M -12.33M -12.09M -11.46M -12.56M -14.01M -12.81M -11.28M -7.95M -4.79M
Interest Income
23.4K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Pretax Income
-10M -11.88M -14.1M -16.44M -16.73M -16.05M -14.58M -12.72M -13.15M -12.33M -12.09M -11.46M -12.56M -13.94M -12.75M -11.21M -7.89M -4.79M
Net Income
-2.25B -11.88M -14.1M -16.44M -16.73M -16.05M -14.58M -12.72M -13.15M -12.33M -12.09M -11.46M -12.56M -13.94M -12.75M -11.21M -7.89M -4.79M
Selling & General & Admin
1.75B 7.43M 8.7M 9.91M 10.06M 9.47M 8.53M 7.19M 7.38M 7.38M 7.34M 7.42M 8.99M 11.25M 10.78M 9.51M 6.65M 3.18M
Research & Development
526.83M 4.45M 5.4M 6.52M 6.67M 6.58M 6.04M 5.53M 5.78M 4.95M 4.75M 4.04M 3.57M 2.76M 2.03M 1.77M 1.3M 1.61M
Other Expenses
-2.27B 1.14K 941.00 1K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
10.02M 11.88M 14.1M 16.44M 16.73M 16.05M 14.58M 12.72M 13.15M 12.33M 12.09M 11.46M 12.56M 14.01M 12.81M 11.28M 7.95M 4.8M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 5.2M 5.2M 5.2M 5.2M n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
10.02M 11.88M 14.1M 16.44M 16.73M 16.05M 14.58M 12.72M 13.15M 12.33M 12.09M 11.46M 12.56M 14.01M 12.81M 11.28M 7.95M 4.8M
Income Tax Expense
n/a n/a n/a -5.11K -8.23K -8.23K -11.13K -6.01K -6.45K -9.07K -6.17K -6.17K -2.62K n/a n/a n/a n/a n/a
Shares Outstanding (Basic)
1.19M 1M 851.55K 818.15K 791.25K 773.65K 673.1K 650.25K 609.3K 581.95K 580.3K 557.4K 513.15K 511.65K 511.23K 505.8K 348.4K 477.05K
Shares Outstanding (Diluted)
1.19M 1M 851.55K 818.15K 791.25K 773.65K 673.1K 650.25K 609.3K 581.95K 580.3K 557.4K 513.15K 511.65K 511.23K 505.8K 348.4K 477.05K
EPS (Basic)
-10.75 -14.07 -17.59 -21.92 -23.26 -23.65 -22.99 -11.79 -13.4 -13 -13.2 -22 -24.8 -31 -28.8 -25.8 -19.4 -9.91
EPS (Diluted)
-10.75 -14.07 -17.59 -21.92 -23.26 -23.65 -22.99 -11.79 -13.4 -13 -13.2 -24.4 -27.2 -33.4 -31.2 -25.8 -19.4 -9.91
EBITDA
-10M -11.88M -14.1M -16.44M -16.73M -16.05M -14.58M -12.72M -13.15M -12.33M -12.09M -11.46M -12.56M -9.94M -8.74M -7.21M -3.88M -4.79M
EBIT
-10M -11.88M -14.1M -16.44M -16.73M -16.05M -14.58M -12.72M -13.15M -12.33M -12.09M -11.46M -12.56M -14.01M -12.81M -11.28M -7.95M -4.79M
Depreciation & Amortization
2.82M 6.94M 11.32M 11.32M 11.62M 10.94M 9.46M 12.72M 9.61M 6.16M 5.93M 2.6M 7.25M 11.32M 10.12M 11.28M 7.95M 3.88M